Compare Eli Lilly And Co (LLY) vs SAP SE (SAP) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

SAP trades at $158.40, down 0.4% today, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 earnings of $2.01 per share, beating estimates, and maintains robust profitability with a 19.58% net income margin. Recent news highlights SAP's focus on AI investments and cost discipline, while EU antitrust concerns were resolved with concessions. Cash flow from operations remains strong at $9.16 billion for 2025, though net cash flow was negative $1.39 billion due to financing activities.

SAP presents a favorable risk-reward profile with a consensus price target of $222.33, implying significant upside. Analyst sentiment is bullish with 53.49% buy ratings. Key risks include competitive pressures in enterprise software and macroeconomic sensitivity. The stock's current valuation at a P/E of 22.38 offers a discount to growth prospects, supported by consistent earnings beats and strategic AI initiatives.